Bone Biologics (BBLG) Invested Capital (2013 - 2017)

Bone Biologics (BBLG) has reported Invested Capital for 5 consecutive years, with $12.9 million the latest figure, recorded in Q3 2017.

• In Q3 2017, Invested Capital rose 43.33% year-over-year to $12.9 million; the TTM figure through Jun 2018 stood at $12.9 million (down 62.72% YoY), while the FY2016 annual figure was $1.2 million, changed N/A from the prior year.
• Invested Capital grew to $12.9 million in Q3 2017 per BBLG's latest filing, from $12.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $12.9 million in Q3 2017 and bottomed at $1.2 million in Q4 2016.
• Historically, Invested Capital has averaged $7.4 million across 5 years, with a median of $9.0 million in 2016.
• Annual changes were most pronounced in 2014 — Invested Capital dropped 26.46% — and 2016, when it soared 135.37%.
• Bone Biologics' Invested Capital stood at $5.1 million in 2013, then decreased by 26.46% to $3.7 million in 2014, then rose by 2.05% to $3.8 million in 2015, then tumbled by 68.62% to $1.2 million in 2016, then jumped by 975.0% to $12.9 million in 2017.
• Business Quant data shows BBLG's Invested Capital at $12.9 million in Q3 2017, $12.2 million in Q2 2017, and $12.2 million in Q1 2017.